Pelthos Therapeutics Inc.
Current- Director 2025 to present
Executive record
Alpha ID: alpha:person:matthew-paulsVersion: public-0As of: 2026-09-29
Chair and CEO of Savara since 2020. Lead Independent Director at Soleno Therapeutics since 2023. Previously President and CEO of Strongbridge Biopharma (2014-2019), which he took public via NASDAQ IPO. Senior commercial leadership roles at Shire, Bristol Myers Squibb, and Johnson & Johnson.
Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.
Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.
Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.
3 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.
sec proxy · Source published: Aug 18, 2026 · Retrieved: Sep 2, 2026
sec filing · Source published: Mar 19, 2026 · Retrieved: May 16, 2026
public source · Source published: Date unavailable · Retrieved: Date unavailable
No published record changes are available in this projection.
Identity
unclaimed
Evidence
source reported
Evaluation
Unknown
Monitoring
Unknown
Authority
Unknown
Freshness
Observed 2026-09-29